Proparco signs its first operation in Malaysia to support the healthcare sector

published on 16 March 2018
  • logo linkedin
  • logo email
Proparco has just invested US$ 4 million in Lablink, a chain of Malaysian medical testing laboratories, as part of its commitment to the Company’s regional development.

Proparco’s investment – its first in the country – is part of a US$ 30 million financing drive by Quadria Capital, a major investment fund that specialises in the healthcare sector. These funds will help the Company to grow and develop its regional operations.

Lablink is a wholly-owned subsidiary of KPJ, one of Malaysia’s biggest hospital operators, and it already has 25 laboratories throughout the country. It provides services ranging from diagnoses of existing pathologies (molecular testing, bacteriology, etc.) to prevention (infectious diseases, allergies, etc.). The Company is also looking to develop higher value-added testing solutions such as analysis of highly infectious diseases. Lablink has been certified as using best quality industry standards.

This project is in phase with Proparco’s development mandate and will improve access to healthcare services in the region.  It will reduce the current mismatch between an insufficient healthcare offering and rapidly increasing demand and will also improve the quality of healthcare on offer. It will therefore help promote Sustainable Development Goals (SDGs) No. 3 (Healthy Lives and Wellbeing) and No. 8 (Decent Work and Economic Growth).


Follow us on Twitter @Proparco
Join our community on LinkedIn